000 01242 a2200349 4500
005 20250517223210.0
264 0 _c20190408
008 201904s 0 0 eng d
022 _a1744-8409
024 7 _a10.1080/1744666X.2018.1490178
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aYoo, Dae Hyun
245 0 0 _aSwitching to biosimilars in the treatment of rheumatic diseases.
_h[electronic resource]
260 _bExpert review of clinical immunology
_c07 2018
300 _a557-571 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aAntirheumatic Agents
_xtherapeutic use
650 0 4 _aBiosimilar Pharmaceuticals
_xtherapeutic use
650 0 4 _aDrug Approval
650 0 4 _aDrug Substitution
650 0 4 _aEvidence-Based Medicine
650 0 4 _aExpert Testimony
650 0 4 _aHumans
650 0 4 _aRandomized Controlled Trials as Topic
650 0 4 _aRheumatic Diseases
_xdrug therapy
700 1 _aChoe, Jung-Yoon
700 1 _aShim, Seung Cheol
700 1 _aSuh, Chang-Hee
773 0 _tExpert review of clinical immunology
_gvol. 14
_gno. 7
_gp. 557-571
856 4 0 _uhttps://doi.org/10.1080/1744666X.2018.1490178
_zAvailable from publisher's website
999 _c28541702
_d28541702